Health
Predictive biomarker for liver cancer associated with survival outcomes, effectiveness of systemic therapy
Medical Xpress·November 19, 2026

Liver cancer was the sixth most common cancer and the third leading cause of cancer-related deaths worldwide in 2022, with hepatocellular carcinoma (HCC) as the most common histological subtype, accounting for approximately 90% of liver cancers. Despite this, biomarkers that predict survival and therapeutic response to atezolizumab plus bevacizumab (Atezo/Bev), a type of systemic therapy in HCC management, have yet to be established in unresectable HCC, in which the tumor cannot be safely treated via surgical removal.
Read the full story at Medical Xpress →